In one week two regulators published their own lab results on unapproved peptide vials. On 5 November 2026 Australia's TGA said its testing found no TB-500 in Synedica "BPC 157 & TB 500 10 mg", "KLOW 80 mg" and "BARBIE KLOW 100 mg", and less retatrutide than labelled, varying between samples, in Synedica "Retatrutide 10 mg". On 6 November 2026 Health Canada said it found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes, in products it seized from Shanghai ERP Peptide Biotechnology Co., Ltd., sold through truenorthbiolabs.ca and bcaxiompeptide.com, and that it seized over 11,400 vials. On 12 November 2026 Health Canada reported Sphingomonas aquatilis/melonis in an injectable seized from Sage & Summit Wellness Co., an Ottawa shop, where some vials were labelled "For Research Purposes Only". None of these names appear in the certificates we mirror. A seller's purity certificate can catch a missing blend component if it prints one. It does not test for bacteria.
Two regulators published lab results on unapproved peptide vials in the same week, and the two findings are different problems. Australia's Therapeutic Goods Administration (TGA) reports that three Synedica blends labelled with TB-500 held no detectable TB-500, and that Synedica retatrutide held less than its label. Health Canada reports bacteria in seized products from a Shanghai maker sold through two Canadian sites, and six days later a different organism in a vial seized from an Ottawa shop. The first is the kind of fault a detailed purity certificate can show. The second is not something a purity certificate tests for. We did not test anything here: every finding below is the regulator's own, and every certificate figure comes from records labs and sellers published.
| Regulator | Published | What was sampled | Finding, in the regulator's words | Action |
|---|---|---|---|---|
| Therapeutic Goods Administration (Australia) | 5 Nov 2026 | Synedica "BPC 157 & TB 500 10 mg", "KLOW 80 mg", "BARBIE KLOW 100 mg", "Retatrutide 10 mg", identified while assisting NSW Police Strike Force Antree | "No TB-500 detected" in the three blends; retatrutide "less ... than stated on the label, with significant variation between samples" | Consumers told to stop using Synedica products; NSW Police inquiries ongoing; unapproved peptides added to TGA priority focus areas |
| Health Canada | 6 Nov 2026 | Products seized from Shanghai ERP Peptide Biotechnology Co., Ltd. and two retailers, truenorthbiolabs.ca and bcaxiompeptide.com | "bacteria such as Acinetobacter seifertii, Acinetobacter nosocomialis, and Propionibacterium (Cutibacterium) acnes" | Entry warrants, over 11,400 vials seized, sites no longer active; ERP Peptide asked to stop selling into Canada; working with the Canada Border Services Agency |
| Health Canada | 12 Nov 2026 | An injectable peptide seized from Sage & Summit Wellness Co., 451 Preston Street, Ottawa | "Sphingomonas aquatilis/melonis" | Seizure after a consumer complaint; the business agreed to stop selling unauthorized peptides in-store and online |
These companies are not vendors we review. We searched every certificate we mirror (Kovera, Janoshik, Particle, Ascension, Swiss Chems and Injectify) and our vendor pages for Synedica, ERP Peptide, True North and BC Axiom on 12 November 2026. None of these names appear in the certificates we mirror.
What did the TGA find in Synedica products?
The TGA's alert, published 5 November 2026, says the products "did not contain what their labels claim". Its results table:
| Product | TGA laboratory finding |
|---|---|
| Synedica BPC 157 & TB 500 10 mg | No TB-500 detected |
| Synedica KLOW 80 mg | No TB-500 detected |
| Synedica BARBIE KLOW 100 mg | No TB-500 detected |
| Synedica Retatrutide 10 mg | Less retatrutide than stated on the label, with significant variation between samples |
The TGA says KLOW is labelled as containing GHK-Cu, BPC-157, TB 500, KPV and vitamin B12, and BARBIE KLOW the same plus melanotan I. That is a longer ingredient list than the four-peptide KLOW on the certificates we read, which name GHK-Cu, BPC-157, TB-500 and KPV (KLOW lab record). The TGA says the products were identified when it assisted the NSW Police State Crime Command with Strike Force Antree, and that it has added unapproved peptide products to its priority focus areas. It also notes that BPC-157, TB-500 and melanotan I are prescription-only medicines in Australia, and that retatrutide has not been approved by the TGA or any comparable regulator.
What did Health Canada find?
Health Canada's public advisory RA-82930, published 6 November 2026, says it "seized and tested unauthorized injectable peptides" from Shanghai ERP Peptide Biotechnology Co., Ltd. and found bacteria, naming Acinetobacter seifertii, Acinetobacter nosocomialis and Propionibacterium (Cutibacterium) acnes. It says it identified two Canadian online retailers selling ERP Peptide products, truenorthbiolabs.ca and bcaxiompeptide.com, obtained court-issued entry warrants, seized products from both, and that the sites are no longer active. In total it says it seized over 11,400 vials from ERP Peptide and the two retailers.
The advisory lists hCG, MOTS-C, NAD+, retatrutide, tesamorelin and tirzepatide as examples of unauthorized products ERP Peptide sold online. Health Canada says it has asked ERP Peptide to stop selling into Canada and is working with the Canada Border Services Agency on shipments. It also tells readers not to use drugs labelled "For Research Use Only - Not for Human Consumption".
What did Health Canada find on 12 November?
Laboratory testing found the bacteria Sphingomonas aquatilis/melonis in an injectable peptide seized from Sage & Summit Wellness Co., a shop at 451 Preston Street in Ottawa. Health Canada said so in a second advisory (RA-82944, 12 November 2026), six days after the first. The seizure followed a consumer complaint that the shop was selling unauthorized peptides in-store and on its website. Health Canada does not say which product was contaminated.
The advisory lists ten injectables (BPC-157, hCG, "Healing Blend" of BPC-157 and TB-500, KLOW, MOTS-C, Selank, Semax, Melanotan-1, retatrutide and tesamorelin) and oral "PURE BPC-157" capsules. It says some seized vials were labelled "For Research Purposes Only", and that this labelling "does not make these products legal" or exempt from regulatory requirements. The business agreed to stop selling unauthorized peptides in-store and on its website.
Our reading: this is Health Canada's second sterility finding in a week. The organism differs, and so does the channel: a physical shop instead of an overseas maker selling through websites. The advisory gives no link between the two cases.
A third regulator spoke the same week. On 4 November 2026 New Zealand's Medsafe published an alert on unapproved peptide products, citing 10 adverse-reaction reports in its database as of 21 October and warning that lab testing promoted by sellers can be misleading; our poison-center and adverse-report page covers it.
What did other regulators do?
Regulators outside Canada and Australia acted on the same kinds of products in the same fortnight. None published a lab result.
| Regulator | Published | Action | Products | Named party |
|---|---|---|---|---|
| IGJ, Netherlands Health and Youth Care Inspectorate | 17 Nov 2026 | Inspection with police on 10 November; more than 8,000 products seized; 3 suspects arrested and released, still suspects | Retatrutide, tirzepatide, semaglutide and bacteriostatic water, offered as slimming medication | An online peptide seller, not named. IGJ says the visit was prompted partly by several reports of people with health complaints after using its products |
| Anvisa, Brazil | 12 Nov 2026 | Recall, and sale, distribution and use suspended | All lots of retatrutide active ingredient and tirzepatide active ingredient lot 20241030, intended for compounded medicines | Distributor Condor Importador & Operador Logístico Ltda. Anvisa cites storage unfit for active ingredients and, for retatrutide, import of an ingredient whose efficacy Anvisa has not approved |
The IGJ and Anvisa notices are in Dutch and Portuguese. The summaries above are our translation. The Anvisa action concerns bulk active ingredient held by a distributor, not finished vials sold to consumers.
What a certificate would and would not have caught
Seller-commissioned certificates and regulator testing measure different things. A certificate reports on one vial a seller chose to send to a lab, and the seller chose to publish it. A regulator samples stock it seized or bought, without the seller's choice.
A missing TB-500 shows up only if the certificate prints each peptide. On a blend, a single purity figure and a combined content figure can look normal with one component absent.
| Record | Blend certificates | Print milligrams per peptide | TB-500 at zero |
|---|---|---|---|
| Kovera, BPC-157 + TB-500 | 69 | 59 | 0 |
| Janoshik, BPC-157 + TB-500 | 12 | 12 | 0 |
| Kovera, KLOW | 52 | 43 | 0 |
| Kovera, GLOW | 40 | 34 | 1 |
Kovera figures are from our mirror of its public records (certificates created 23 January to 2 July 2026, read 12 November 2026); Janoshik's from its public reports to 30 June 2026. The one zero is Glacier Aminos' Glow, Kovera report KVR-2026-50085D (17 May 2026): 51.01 mg against a 70 mg label, purity 99.91%, the component table printing GHK-Cu at 51.01 mg and BPC-157 and TB-500 at zero, identity "Unknown". Kovera failed it. A 99.91% purity figure on that vial shows why the headline purity line cannot answer the TGA's question, and only the component table can. The KLOW fail in the record, TTX EDGE's Klow KVR-2026-5953A8, held 24.82 mg against 80 mg with blend identity "Unknown" (detail). Among Kovera's BPC-157 and TB-500 blends, the one fail is KVR-2026-550573, at 35.54 mg against a 40 mg label (Wolverine blend record).
Under-filled retatrutide is rare on published certificates. Across the five sources we mirror, 319 of 322 retatrutide results with an identity test confirmed retatrutide, and 2 of 307 results with a measured mass were under 90% of label. The median vial held 110.2% (retatrutide lab record). The TGA's second point, "significant variation between samples", is one a single-vial certificate cannot show at all: it describes one vial from one lot.
Bacteria are outside a purity certificate. Purity, identity and content tests measure the peptide. They do not culture the vial for living organisms. That takes a separate sterility test, usually an add-on the seller pays for. In our Kovera mirror, 705 of 1,760 peptide certificates report a sterility result, all no growth, and only 101 of the 706 that list an incubation period list 14 days; 179 list 0 days. An endotoxin line is a different test again: it measures a bacterial cell-wall toxin, not live bacteria (how endotoxin and sterility differ). A clean sterility result on one lot says nothing about another lot, or about a vial after it has been opened.
What the notices do not say
- Health Canada does not say how many vials it tested, which of the listed products carried which organism, how much bacteria it found, or whether it tested for endotoxin. It does not say the two retailers made the products; it says they sold products from ERP Peptide. Its 12 November advisory on Sage & Summit Wellness Co. does not say which product carried Sphingomonas, how many vials were seized or tested, or where the shop sourced its stock.
- The TGA gives no milligram figures, no percentages and no number of samples. It reports nothing on the other labelled ingredients in the three blends (BPC-157, GHK-Cu, KPV, vitamin B12, melanotan I), and does not name a seller beyond the Synedica brand.
- Neither notice names a lab method, and neither mentions any seller's certificate. Nothing in either links these products to any vendor we cover.
Our reading: the TGA result is the failure mode the more detailed blend certificates are built to show, when a seller publishes one for that lot. The Health Canada result is the one most research-peptide certificates never look for. Neither notice tells you anything about a vial from another brand. How we read certificates is set out in our methodology.
Sources
- TGA, "TGA testing finds unapproved peptides do not contain what their labels claim" - safety alert published 5 November 2026; results table, label contents, Strike Force Antree; read 12 November 2026
- Health Canada, "Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs" - public advisory RA-82930, published 6 November 2026; organisms, retailers, 11,400+ vials; read 12 November 2026
- Health Canada, "Health Canada warns about unauthorized peptides, including contaminated injectable" - public advisory RA-82944, published 12 November 2026; Sage & Summit Wellness Co., Sphingomonas aquatilis/melonis, product list, "For Research Purposes Only" labels; read 19 November 2026
- IGJ (Netherlands), "IGJ neemt partij illegale geneesmiddelen in beslag" - news release, 17 November 2026; 10 November inspection, 8,000+ products, 3 arrests; read 19 November 2026
- Anvisa (Brazil), "Anvisa determina recolhimento de insumos tirzepatida e retatrutida por armazenamento irregular" - news release, 12 November 2026; Resolution 4.422/2026; read 19 November 2026
- Medsafe (New Zealand), the risks of unapproved peptide products - alert, 4 November 2026
- Kovera Labs certificate verifier: KVR-2026-50085D, KVR-2026-5953A8, KVR-2026-550573
- Our records: Kovera certificate mirror, KLOW lab record, Wolverine blend record, retatrutide lab record, endotoxin on a peptide COA
Frequently asked
What did Health Canada find in the seized peptides?
Health Canada says it seized and tested unauthorized injectable peptides from Shanghai ERP Peptide Biotechnology Co., Ltd. and found bacteria such as Acinetobacter seifertii, Acinetobacter nosocomialis and Propionibacterium (Cutibacterium) acnes. Its 6 November 2026 advisory (RA-82930) lists hCG, MOTS-C, NAD+, retatrutide, tesamorelin and tirzepatide as examples of products ERP Peptide sold online. It does not say which of those products carried which organism.
Which websites did Health Canada name?
Two Canadian online retailers, truenorthbiolabs.ca and bcaxiompeptide.com, which Health Canada says sold ERP Peptide products. It says it obtained court-issued entry warrants, seized products from both, and that the websites are no longer active. Neither is a vendor we review.
What did the TGA find in Synedica KLOW?
The TGA reports "No TB-500 detected" in Synedica KLOW 80 mg, Synedica BARBIE KLOW 100 mg and Synedica BPC 157 & TB 500 10 mg. It says KLOW is labelled as GHK-Cu, BPC-157, TB 500, KPV and vitamin B12, and BARBIE KLOW adds melanotan I. The alert gives no result for the other labelled ingredients.
Did the TGA say how much retatrutide was in the Synedica vials?
No. The 5 November 2026 alert says Synedica Retatrutide 10 mg "contained less retatrutide than stated on the label, with significant variation between samples". It gives no milligram figure, no percentage and no sample count.
Would a certificate of analysis have caught these problems?
Partly. A blend certificate that prints milligrams for each peptide would show a missing TB-500: in our Kovera mirror, 59 of 69 BPC-157 and TB-500 blend certificates do, and one GLOW certificate shows TB-500 at zero. A purity, identity and content certificate does not look for living bacteria. That needs a sterility test, which 705 of 1,760 Kovera certificates report. Any certificate describes the vial a seller chose to submit, not stock a regulator seized.
Do Synedica or ERP Peptide appear in vialaudit's lab data?
No. We searched our mirrored certificates from Kovera, Janoshik, Particle, Ascension, Swiss Chems and Injectify, and our vendor pages, for Synedica, ERP Peptide, True North and BC Axiom on 12 November 2026. None of the names appear.